Journal Article
. 2019 Jan; 196(3):345-352.
doi: 10.1111/cei.13264.

Effect of pembrolizumab on CD4+ CD25+ , CD4+ LAP+ and CD4+ TIM-3+ T cell subsets

S M Toor 1 V Sasidharan Nair 1 G Pfister 2 E Elkord 1 
  • PMID: 30693485
  •     29 References
  •     9 citations


Tumor immune evasion involves the expansion of avidly proliferating immunosuppressive cells and inhibition of effector T cell proliferation. Immune checkpoints (IC) block the activation pathways of tumor-reactive T cells. IC pathways are often exploited by tumor cells to evade immune destruction, and blocking these pathways through IC inhibitors (ICI) has shown promising results in multiple malignancies. In this study, we investigated the effects of an ICI, pembrolizumab, on various T cell subsets in vitro. We compared the suppressive activity of CD4+ CD25+ regulatory T cells (conventional Treg ) with T cells expressing T cell immunoglobulin-3+ (TIM-3+ ) and latency-associated peptide (LAP)+ T cells. We found that LAP-expressing T cells were more suppressive than conventional Treg , but TIM-3-expressing T cells were not suppressive. Our results show that pembrolizumab does not modulate functions of Treg and mediates its immunostimulatory effects via the release of effector T cells from suppression. These findings may assist in the development of agents designed to intervene in IC pathways to overcome Treg resistance to ICI.

Keywords: cell activation; cell proliferation; regulatory T cells.

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.
Laurent Monney, Catherine A Sabatos, +9 authors, Vijay K Kuchroo.
Nature, 2002 Feb 02; 415(6871). PMID: 11823861
Highly Cited.
PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2008 Jan 05; 26. PMID: 18173375
Highly Cited. Review.
T cell activation.
Jennifer E Smith-Garvin, Gary A Koretzky, Martha S Jordan.
Annu Rev Immunol, 2009 Jan 10; 27. PMID: 19132916    Free PMC article.
Highly Cited. Review.
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
Christy Ralph, Eyad Elkord, +5 authors, Fiona C Thistlethwaite.
Clin Cancer Res, 2010 Feb 25; 16(5). PMID: 20179239
FOXP3+ regulatory T cells in the human immune system.
Shimon Sakaguchi, Makoto Miyara, Cristina M Costantino, David A Hafler.
Nat Rev Immunol, 2010 Jun 19; 10(7). PMID: 20559327
Highly Cited. Review.
Interleukin-2 receptor signaling: at the interface between tolerance and immunity.
Thomas R Malek, Iris Castro.
Immunity, 2010 Aug 25; 33(2). PMID: 20732639    Free PMC article.
Highly Cited. Review.
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Kaori Sakuishi, Lionel Apetoh, +3 authors, Ana C Anderson.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819927    Free PMC article.
Highly Cited.
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Sameena Khan, Deborah J Burt, +3 authors, Eyad Elkord.
Clin Immunol, 2010 Nov 09; 138(1). PMID: 21056008
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.
Dennis Lindau, Paul Gielen, +2 authors, Gosse J Adema.
Immunology, 2012 Dec 12; 138(2). PMID: 23216602    Free PMC article.
Highly Cited. Review.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Tim-3: an activation marker and activation limiter of innate immune cells.
Gencheng Han, Guojiang Chen, Beifen Shen, Yan Li.
Front Immunol, 2013 Dec 18; 4. PMID: 24339828    Free PMC article.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Emanuela Romano, Monika Kusio-Kobialka, +7 authors, Daniel E Speiser.
Proc Natl Acad Sci U S A, 2015 Apr 29; 112(19). PMID: 25918390    Free PMC article.
Highly Cited.
T-cell exhaustion in the tumor microenvironment.
Y Jiang, Y Li, B Zhu.
Cell Death Dis, 2015 Jun 19; 6. PMID: 26086965    Free PMC article.
Highly Cited. Review.
Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP.
Eyad Elkord, May Abd Al Samid, Belal Chaudhary.
Oncotarget, 2015 Sep 08; 6(24). PMID: 26343373    Free PMC article.
T Cell Fate at the Single-Cell Level.
Veit R Buchholz, Ton N M Schumacher, Dirk H Busch.
Annu Rev Immunol, 2015 Dec 17; 34. PMID: 26666651
PD-1 Blockade Expands Intratumoral Memory T Cells.
Antoni Ribas, Daniel Sanghoon Shin, +14 authors, Begoña Comin-Anduix.
Cancer Immunol Res, 2016 Jan 21; 4(3). PMID: 26787823    Free PMC article.
Highly Cited.
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
Ana C Anderson, Nicole Joller, Vijay K Kuchroo.
Immunity, 2016 May 19; 44(5). PMID: 27192565    Free PMC article.
Highly Cited. Review.
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting.
Belal Chaudhary, Eyad Elkord.
Vaccines (Basel), 2016 Aug 12; 4(3). PMID: 27509527    Free PMC article.
Highly Cited. Review.
Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk.
Jing Li, Gulidanna Shayan, +6 authors, Robert L Ferris.
Oncoimmunology, 2016 Nov 18; 5(10). PMID: 27853635    Free PMC article.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas.
Cell, 2017 Feb 12; 168(4). PMID: 28187290    Free PMC article.
Highly Cited. Review.
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
Alice O Kamphorst, Rathi N Pillai, +16 authors, Suresh S Ramalingam.
Proc Natl Acad Sci U S A, 2017 Apr 28; 114(19). PMID: 28446615    Free PMC article.
Highly Cited.
In-vitro effect of pembrolizumab on different T regulatory cell subsets.
S M Toor, A S Syed Khaja, I Alkurd, E Elkord.
Clin Exp Immunol, 2017 Oct 01; 191(2). PMID: 28963773    Free PMC article.
De-novo and acquired resistance to immune checkpoint targeting.
Nicholas L Syn, Michele W L Teng, Tony S K Mok, Ross A Soo.
Lancet Oncol, 2017 Dec 07; 18(12). PMID: 29208439
Highly Cited. Review.
Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function.
Jacob V Gorman, John D Colgan.
Immunology, 2018 Jan 10; 154(3). PMID: 29315553    Free PMC article.
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Varun Sasidharan Nair, Eyad Elkord.
Immunol Cell Biol, 2018 Jan 24; 96(1). PMID: 29359507
Highly Cited. Review.
FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.
Theresa L Whiteside.
Expert Opin Ther Targets, 2018 Mar 14; 22(4). PMID: 29532697    Free PMC article.
Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients.
Zhuqing Liu, Elizabeth L McMichael, +6 authors, Robert L Ferris.
Clin Cancer Res, 2018 May 02; 24(18). PMID: 29712685    Free PMC article.
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
Fei Tang, Xuexiang Du, +2 authors, Yang Liu.
Cell Biosci, 2018 May 02; 8. PMID: 29713453    Free PMC article.
Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.
A Charlotte M T de Wolf, Carla A Herberts, Marcel H N Hoefnagel.
Front Med (Lausanne), 2020 Apr 18; 7. PMID: 32300597    Free PMC article.
Systematic Review.
Transcriptomic Profiling of Tumor-Infiltrating CD4+TIM-3+ T Cells Reveals Their Suppressive, Exhausted, and Metastatic Characteristics in Colorectal Cancer Patients.
Varun Sasidharan Nair, Salman M Toor, +8 authors, Eyad Elkord.
Vaccines (Basel), 2020 Feb 12; 8(1). PMID: 32041340    Free PMC article.
Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection.
Evan J Lipson, Fizza F Naqvi, +4 authors, Daniel C Brennan.
Am J Transplant, 2020 Mar 19; 20(8). PMID: 32185872    Free PMC article.
Turning the Tide Against Regulatory T Cells.
SeongJun Han, Aras Toker, Zhe Qi Liu, Pamela S Ohashi.
Front Oncol, 2019 May 07; 9. PMID: 31058083    Free PMC article.
Transcriptomic Analyses of Myeloid-Derived Suppressor Cell Subsets in the Circulation of Colorectal Cancer Patients.
Varun Sasidharan Nair, Reem Saleh, +2 authors, Eyad Elkord.
Front Oncol, 2020 Sep 29; 10. PMID: 32984004    Free PMC article.
Differential gene expression of tumor-infiltrating CD33+ myeloid cells in advanced- versus early-stage colorectal cancer.
Salman M Toor, Rowaida Z Taha, +4 authors, Eyad Elkord.
Cancer Immunol Immunother, 2020 Oct 02; 70(3). PMID: 33000418    Free PMC article.
Molecular Classification and Tumor Microenvironment Characterization of Gallbladder Cancer by Comprehensive Genomic and Transcriptomic Analysis.
Nobutaka Ebata, Masashi Fujita, +10 authors, Hidewaki Nakagawa.
Cancers (Basel), 2021 Feb 14; 13(4). PMID: 33578820    Free PMC article.
Transcriptome of Tumor-Infiltrating T Cells in Colorectal Cancer Patients Uncovered a Unique Gene Signature in CD4+ T Cells Associated with Poor Disease-Specific Survival.
Salman M Toor, Varun Sasidharan Nair, +8 authors, Eyad Elkord.
Vaccines (Basel), 2021 May 01; 9(4). PMID: 33916009    Free PMC article.
Recruitment and Expansion of Tregs Cells in the Tumor Environment-How to Target Them?
Justine Cinier, Margaux Hubert, +5 authors, Christine Ménétrier-Caux.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33924428    Free PMC article.